Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

After a soggy start to the day, we’ll see big afternoon improvements. Clouds will linger for a good part of the morning in Boston as clearing skies inch from west to east. The afternoon will turn ...